1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

 
• By Jessica Merrill

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

pillar
J&J outlined a broad development plan for nipocalimab, which it hopes will be a new pillar brand • Source: Alamy

Johnson & Johnson is looking to continue its commercial success in immunology by building in new therapeutic areas as categories like psoriasis and rheumatoid arthritis have matured and the competitive dynamics have intensified. The company has homed in on the neonatal Fc-receptor (FcRn) inhibitor nipocalimab as the next pillar in its immunology portfolio, targeting 11 initial indications for various autoantibody-driven diseases.

J&J is taking a "pathway-centric" development strategy with nipocalimab, which the company gained with the $6.5bn acquisition of Momenta Pharmaceuticals, Inc. last year. (Also see "J&J Seeks Command Position In FcRn Space With Momenta Buyout" - Scrip, 19 August, 2020.) The acquisition marked J&J's move into autoantibody-driven diseases, in which an antibody attacks an individual's own tissues

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.